• FDA-Approved Poteligeo for Two Types of Cutaneous T-cell Lymphoma
  • Cellectar and Orano Med Collaborating to Advance Innovative Anti-Cancer Therapy
  • First Patient Dosed in Phase 2 Trial of ADCT-402 in DLBCL
  • Hope Matters As I Celebrate My 10-Year ‘Diagnosiversary’
  • Poteligeo Approved in US for Treating 2 Cutaneous T-cell Lymphoma Subtypes
  • Gazyva-Revlimid Combo Shows Promise for Follicular Lymphoma Patients in Clinical Trial
  • New Fluorescent Probe Able to Identify, Track Evasive Cancer Stem Cells in Mice, Study Reports
  • Compound Puts Cancer Cells into ‘Permanent Sleep’ in Mouse Study
  • Gazyva Infusion Could Be Shorter for Some NHL Patients, Study Finds
  • Venclexta Triple Combo in NHL Patients Produces Long-lasting Responses in Phase 1 Trial
  • Ranimustine-based Conditioning Regimen Before Stem Cell Transplant Effective in DLBCL Patients, Study Suggests
  • Dietary Supplement with Probiotics, Digestive Enzymes May Protect Gut from Chemotherapy Side Effects